NovaScan

NovaScan Inc. is a medical device company based in Chicago, IL, that specializes in cancer detection technologies. Founded in January 2017, the company has developed a patented technology platform that combines machine learning with bio-spectral impedance to detect and locate cancer both in vivo and ex vivo. This innovative approach allows for rapid diagnosis without the need for expensive equipment. The company's core products include the Canary device, which assesses the presence of cancer in biopsy cores for immediate diagnosis, and MarginScan, designed to detect cancer in the margins of surgical excisions. MarginScan is being commercialized in partnership with PHC Holdings, focusing initially on non-melanoma skin cancer, with a launch planned for late 2025. NovaScan's technology is notable for providing instantaneous results with high accuracy, making it practical for clinical use. Led by a team of experts in healthcare and medical technology, NovaScan targets healthcare providers and cancer treatment centers to enhance cancer diagnosis and surgical outcomes. The company's strategic partnerships position it well within the oncology market.

• Employees 13
• Annual Revenue $27743000
• Total Funding $13175000